JP2010532768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532768A5 JP2010532768A5 JP2010515355A JP2010515355A JP2010532768A5 JP 2010532768 A5 JP2010532768 A5 JP 2010532768A5 JP 2010515355 A JP2010515355 A JP 2010515355A JP 2010515355 A JP2010515355 A JP 2010515355A JP 2010532768 A5 JP2010532768 A5 JP 2010532768A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- tumors
- leukemia
- group
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007032507.1 | 2007-07-12 | ||
| DE102007032507A DE102007032507A1 (de) | 2007-07-12 | 2007-07-12 | Pyridazinonderivate |
| PCT/EP2008/003473 WO2009006959A1 (de) | 2007-07-12 | 2008-04-29 | Pyridazinonderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532768A JP2010532768A (ja) | 2010-10-14 |
| JP2010532768A5 true JP2010532768A5 (OSRAM) | 2011-07-28 |
| JP5426543B2 JP5426543B2 (ja) | 2014-02-26 |
Family
ID=39638671
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515355A Active JP5426543B2 (ja) | 2007-07-12 | 2008-04-29 | ピリダジノン誘導体 |
| JP2010515398A Active JP5426544B2 (ja) | 2007-07-12 | 2008-07-04 | ピリミジニル−ピリダジノン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515398A Active JP5426544B2 (ja) | 2007-07-12 | 2008-07-04 | ピリミジニル−ピリダジノン誘導体 |
Country Status (36)
| Country | Link |
|---|---|
| US (8) | US8580781B2 (OSRAM) |
| EP (3) | EP2164843B1 (OSRAM) |
| JP (2) | JP5426543B2 (OSRAM) |
| KR (2) | KR101553418B1 (OSRAM) |
| CN (2) | CN101743241B (OSRAM) |
| AR (2) | AR066543A1 (OSRAM) |
| AU (2) | AU2008274670B2 (OSRAM) |
| BR (2) | BRPI0814616B1 (OSRAM) |
| CA (2) | CA2693600C (OSRAM) |
| CL (1) | CL2008001392A1 (OSRAM) |
| CO (2) | CO6170360A2 (OSRAM) |
| CY (4) | CY1113137T1 (OSRAM) |
| DE (1) | DE102007032507A1 (OSRAM) |
| DK (3) | DK2754660T3 (OSRAM) |
| EA (2) | EA016782B1 (OSRAM) |
| EC (2) | ECSP109953A (OSRAM) |
| ES (3) | ES2614283T3 (OSRAM) |
| FR (1) | FR22C1024I2 (OSRAM) |
| HR (3) | HRP20150031T1 (OSRAM) |
| HU (2) | HUE030519T2 (OSRAM) |
| IL (2) | IL203091A (OSRAM) |
| LT (2) | LT2754660T (OSRAM) |
| LU (1) | LUC00264I2 (OSRAM) |
| MY (2) | MY153727A (OSRAM) |
| NL (1) | NL301176I2 (OSRAM) |
| NO (1) | NO2022015I1 (OSRAM) |
| NZ (1) | NZ583187A (OSRAM) |
| PE (1) | PE20090287A1 (OSRAM) |
| PL (3) | PL2754660T3 (OSRAM) |
| PT (3) | PT2754660T (OSRAM) |
| SG (1) | SG183739A1 (OSRAM) |
| SI (3) | SI2754660T1 (OSRAM) |
| TW (1) | TWI501768B (OSRAM) |
| UA (2) | UA99621C2 (OSRAM) |
| WO (2) | WO2009006959A1 (OSRAM) |
| ZA (1) | ZA201001023B (OSRAM) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007038957A1 (de) * | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
| DE102007041115A1 (de) * | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
| DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008019907A1 (de) * | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008028905A1 (de) * | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| DE102008037790A1 (de) * | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| DK2361250T3 (da) * | 2008-12-22 | 2013-11-04 | Merck Patent Gmbh | Nye polymorfe former af 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-on-dihydrogenphosphat og fremgangsmåder til fremstilling deraf |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| JP5719781B2 (ja) * | 2009-01-08 | 2015-05-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ３−（１−｛３−［５−（１−メチル−ピペリジン−４−イルメトキシ）−ピリミジン−２−イル］−ベンジル｝−６−オキソ−１，６−ジヒドロ−ピリダジン−３−イル）−ベンゾニトリル塩酸塩の新規な多形体およびその製法 |
| EP2221053A1 (de) * | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| DE102011101482B4 (de) | 2011-05-13 | 2017-05-11 | Thyssenkrupp Presta Aktiengesellschaft | Sensoranordnung für eine drehbare Welle |
| JP6240658B2 (ja) * | 2012-03-19 | 2017-11-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体と他の抗腫瘍化合物との組み合わせ |
| KR101842645B1 (ko) * | 2012-04-12 | 2018-03-29 | 한국화학연구원 | 신규한 히드라진온이 치환된 피리미딘 유도체 및 그의 용도 |
| BR112015007870B1 (pt) * | 2012-10-11 | 2021-12-07 | Merck Patent Gmbh | Composição compreendendo derivado de 6-oxo-1,6-di-hidro-piridazina e inibidor de mek, e seus usos |
| BR112015008279A2 (pt) * | 2012-11-02 | 2017-07-04 | Merck Patent Gmbh | derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc) |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| EP2935253B1 (en) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| PT2953944T (pt) * | 2013-02-07 | 2017-08-01 | Merck Patent Gmbh | Derivados de piridazinona-amidas |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| SG11201602996RA (en) * | 2013-10-18 | 2016-05-30 | Celgene Quanticel Res Inc | Bromodomain inhibitors |
| CN110437298A (zh) * | 2013-12-04 | 2019-11-12 | 盖尔梅德研究与发展有限公司 | Aramchol盐 |
| JP2017502055A (ja) * | 2014-01-07 | 2017-01-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗癌活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体のゲフィチニブとの併用 |
| MY191613A (en) * | 2014-01-07 | 2022-07-03 | Merck Patent Gmbh | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc) |
| US9919034B2 (en) | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
| LT3125894T (lt) * | 2014-04-01 | 2020-12-10 | Merck Sharp & Dohme Corp. | Živ atvirkštinės transkriptazės inhibitorių provaistai |
| US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
| US9642794B2 (en) * | 2014-08-18 | 2017-05-09 | Tamir Biotechnology, Inc. | Antiviral pharmaceutical for topical administration |
| CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1246273B (en) | 2014-12-01 | 2019-12-06 | 恒翼生物医药(上海)股份有限公司 | Substituted pyridines as bromodomain inhibitors |
| TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
| CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| NZ731770A (en) * | 2014-12-11 | 2023-05-26 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative |
| AU2015360005A1 (en) * | 2014-12-12 | 2017-07-27 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor |
| EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| WO2016192831A1 (en) | 2015-05-29 | 2016-12-08 | Merck Patent Gmbh | Compositions of anions and cations with pharmacological activity |
| AU2016277827B2 (en) | 2015-06-15 | 2021-04-29 | Orgenesis Inc. | Pharmaceuticals for treatment of viral infections of the eye |
| LT3533787T (lt) | 2016-10-27 | 2020-11-25 | Fujian Cosunter Pharmaceutical Co., Ltd. | Piridono junginys kaip c-met inhibitorius |
| KR20190078646A (ko) * | 2016-11-18 | 2019-07-04 | 머크 샤프 앤드 돔 코포레이션 | 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체 |
| KR102636383B1 (ko) * | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| TWI797176B (zh) | 2017-10-17 | 2023-04-01 | 西班牙商帕羅製藥有限公司 | ４-胺基嘧啶化合物之合成 |
| EP3719012B1 (en) | 2017-11-24 | 2024-03-06 | Medshine Discovery Inc. | N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors |
| EP3786155B1 (en) * | 2018-04-26 | 2023-08-16 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor |
| CN108752322A (zh) | 2018-09-12 | 2018-11-06 | 广州新民培林医药科技有限公司 | 一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用 |
| CN113272014B (zh) | 2018-11-06 | 2026-01-27 | 艾知怀斯治疗学公司 | 哒嗪酮化合物及其用途 |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| PL3877376T3 (pl) | 2018-11-06 | 2024-02-19 | Edgewise Therapeutics, Inc. | Pochodne pirydazynonu i ich zastosowania |
| KR20210107069A (ko) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
| KR102660608B1 (ko) * | 2019-02-01 | 2024-04-26 | 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. | c-Met억제제로서 피리미디닐기를 포함하는 삼환식 화합물 |
| JP7603592B2 (ja) | 2019-02-05 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| CN119638696A (zh) | 2019-02-06 | 2025-03-18 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| AU2020240059B2 (en) * | 2019-03-20 | 2025-10-23 | Gfb (Abc), Llc | Pyridazinones and methods of use thereof |
| LT3996688T (lt) | 2019-07-10 | 2023-12-27 | Merck Patent Gmbh | Farmacinis preparatas |
| CN114174298B (zh) * | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| WO2022063869A2 (en) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| KR102489160B1 (ko) * | 2021-05-26 | 2023-01-18 | 주식회사 이노큐어테라퓨틱스 | 피페리딘디온 유도체 |
| WO2022250350A1 (ko) * | 2021-05-26 | 2022-12-01 | 주식회사 이노큐어테라퓨틱스 | 피페리딘디온 유도체 |
| AU2022286643A1 (en) | 2021-06-04 | 2024-01-18 | Merck Patent Gmbh | Compounds for the treatment of glioblastoma |
| WO2023091606A1 (en) * | 2021-11-17 | 2023-05-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN114394957B (zh) * | 2021-12-24 | 2023-05-09 | 武汉九州钰民医药科技有限公司 | Met抑制剂盐酸特泊替尼的制备方法 |
| TW202421146A (zh) | 2022-07-08 | 2024-06-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合 |
| CN116496253B (zh) * | 2022-08-19 | 2024-10-11 | 中国人民解放军军事科学院军事医学研究院 | c-MET蛋白靶向降解剂及其医药应用 |
| CN115583939A (zh) * | 2022-11-04 | 2023-01-10 | 苏州莱安医药化学技术有限公司 | 一种特泊替尼中间体的合成方法 |
| CN120569390A (zh) * | 2022-11-22 | 2025-08-29 | 因诺库尔治疗公司 | 包括新型c-MET蛋白配体的降解剂和包括其的药物组合物 |
| WO2024112119A1 (ko) * | 2022-11-22 | 2024-05-30 | 주식회사 이노큐어테라퓨틱스 | cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물 |
| CN116082309B (zh) * | 2023-01-04 | 2023-10-24 | 广东莱恩医药研究院有限公司 | 嘧啶衍生物1d228盐酸盐晶型及其制备方法和应用 |
| CN116768868B (zh) * | 2023-08-15 | 2023-12-08 | 云南省药物研究所 | 一种哒嗪酮硫代衍生物及其制备方法和应用 |
| CN118084871B (zh) * | 2024-04-29 | 2024-07-09 | 中国药科大学 | 一种靶向降解c-Met蛋白的化合物及其制法和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3853946A (en) | 1971-11-11 | 1974-12-10 | Hoffmann La Roche | Process for the preparation of aminomethylene malononitrile |
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE19604388A1 (de) | 1996-02-07 | 1997-08-14 | Merck Patent Gmbh | Arylalkyl-diazinone |
| AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| HUP0100059A3 (en) | 1997-11-19 | 2002-08-28 | Kowa Co | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AUPQ462299A0 (en) | 1999-12-13 | 2000-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| US6242461B1 (en) | 2000-01-25 | 2001-06-05 | Pfizer Inc. | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
| DE10010422A1 (de) | 2000-03-03 | 2001-09-06 | Bayer Ag | 6-Carboxyphenylpyridazinon-Derivate und ihre Verwendung |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| CA2411160A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| CA2462525A1 (en) | 2001-10-31 | 2003-05-08 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Type 4 phosphodiesterase inhibitors and uses thereof |
| JP2005519895A (ja) * | 2002-01-18 | 2005-07-07 | ファルマシア・コーポレーション | Ｐ３８阻害剤としての置換ピリダジノン |
| UA77526C2 (en) | 2002-06-07 | 2006-12-15 | Sanofi Aventis | Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy |
| EP1572682A4 (en) | 2002-12-20 | 2008-01-23 | Pharmacia Corp | ACYCLIC PYRAZOLE COMPOUNDS |
| JP2007516180A (ja) | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| US7959919B2 (en) * | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
| US20070043057A1 (en) | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| US20070015771A1 (en) | 2004-07-29 | 2007-01-18 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| TW200612918A (en) | 2004-07-29 | 2006-05-01 | Threshold Pharmaceuticals Inc | Lonidamine analogs |
| WO2007044796A2 (en) | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
| DE102005055355A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| DE102005055354A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
| EP1963329B1 (en) | 2005-11-30 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| RS55630B1 (sr) | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| PE20091079A1 (es) | 2007-10-16 | 2009-08-24 | Novartis Ag | Compuestos heterociclicos como moduladores npy y2 |
| KR20100089090A (ko) | 2007-10-25 | 2010-08-11 | 아스트라제네카 아베 | 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체 |
| MX2010004705A (es) | 2007-10-31 | 2010-05-27 | Nissan Chemical Ind Ltd | Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7. |
| TW200927115A (en) | 2007-11-16 | 2009-07-01 | Boehringer Ingelheim Int | Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| US7816540B2 (en) | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
| BRPI0821141A2 (pt) | 2007-12-21 | 2015-06-16 | Hoffmann La Roche | Derivados de heteroarila como antagonistas do receptor de orexina |
| EP2225239B1 (en) | 2007-12-21 | 2014-10-22 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| CL2008003785A1 (es) | 2007-12-21 | 2009-10-09 | Du Pont | Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada. |
| JP5498396B2 (ja) | 2007-12-21 | 2014-05-21 | パラウ・フアルマ・ソシエダツド・アノニマ | ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体 |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| EP2242483B1 (en) | 2007-12-21 | 2013-02-20 | Synthon B.V. | Raloxifene composition |
| EA017144B1 (ru) | 2007-12-21 | 2012-10-30 | Астразенека Аб | N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором |
| AR069869A1 (es) | 2007-12-21 | 2010-02-24 | Exelixis Inc | Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer. |
| GB0725059D0 (en) | 2007-12-21 | 2008-01-30 | Syngenta Participations Ag | Novel pyridazine derivatives |
| EP2072506A1 (de) | 2007-12-21 | 2009-06-24 | Bayer CropScience AG | Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| CN101538245B (zh) * | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| EP2328586A2 (en) * | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| JP5390610B2 (ja) * | 2008-07-25 | 2014-01-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| WO2010113986A1 (ja) * | 2009-03-30 | 2010-10-07 | 住友化学株式会社 | ピリダジノン化合物の有害節足動物防除用途 |
| AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
-
2007
- 2007-07-12 DE DE102007032507A patent/DE102007032507A1/de not_active Withdrawn
-
2008
- 2008-04-29 CA CA2693600A patent/CA2693600C/en active Active
- 2008-04-29 WO PCT/EP2008/003473 patent/WO2009006959A1/de not_active Ceased
- 2008-04-29 SG SG2012061180A patent/SG183739A1/en unknown
- 2008-04-29 EP EP08758359.7A patent/EP2164843B1/de active Active
- 2008-04-29 BR BRPI0814616-0A patent/BRPI0814616B1/pt active IP Right Grant
- 2008-04-29 JP JP2010515355A patent/JP5426543B2/ja active Active
- 2008-04-29 UA UAA201000999A patent/UA99621C2/ru unknown
- 2008-04-29 AU AU2008274670A patent/AU2008274670B2/en active Active
- 2008-04-29 PL PL14001269T patent/PL2754660T3/pl unknown
- 2008-04-29 EP EP14001269.1A patent/EP2754660B1/de active Active
- 2008-04-29 CN CN2008800241496A patent/CN101743241B/zh active Active
- 2008-04-29 PT PT140012691T patent/PT2754660T/pt unknown
- 2008-04-29 EA EA201000093A patent/EA016782B1/ru unknown
- 2008-04-29 ES ES14001269T patent/ES2614283T3/es active Active
- 2008-04-29 ES ES08758359T patent/ES2526352T3/es active Active
- 2008-04-29 NZ NZ583187A patent/NZ583187A/en unknown
- 2008-04-29 KR KR1020107002999A patent/KR101553418B1/ko active Active
- 2008-04-29 SI SI200831759A patent/SI2754660T1/sl unknown
- 2008-04-29 US US12/668,535 patent/US8580781B2/en active Active
- 2008-04-29 LT LTEP14001269.1T patent/LT2754660T/lt unknown
- 2008-04-29 PL PL08758359T patent/PL2164843T3/pl unknown
- 2008-04-29 HU HUE14001269A patent/HUE030519T2/en unknown
- 2008-04-29 MY MYPI2010000066A patent/MY153727A/en unknown
- 2008-04-29 HR HRP20150031AT patent/HRP20150031T1/hr unknown
- 2008-04-29 DK DK14001269.1T patent/DK2754660T3/en active
- 2008-04-29 DK DK08758359.7T patent/DK2164843T3/en active
- 2008-04-29 PT PT87583597T patent/PT2164843E/pt unknown
- 2008-04-29 SI SI200831367T patent/SI2164843T1/sl unknown
- 2008-05-12 CL CL2008001392A patent/CL2008001392A1/es unknown
- 2008-05-12 PE PE2008000825A patent/PE20090287A1/es active IP Right Grant
- 2008-05-13 TW TW097117607A patent/TWI501768B/zh active
- 2008-05-13 AR ARP080102013A patent/AR066543A1/es active IP Right Grant
- 2008-07-04 AU AU2008274534A patent/AU2008274534B2/en active Active
- 2008-07-04 EP EP08773881A patent/EP2164844B1/de active Active
- 2008-07-04 US US12/668,491 patent/US8329692B2/en active Active
- 2008-07-04 CN CN2008800230561A patent/CN101687857B/zh active Active
- 2008-07-04 HR HRP20120661AT patent/HRP20120661T1/hr unknown
- 2008-07-04 MY MYPI2010000061A patent/MY163477A/en unknown
- 2008-07-04 ES ES08773881T patent/ES2388883T3/es active Active
- 2008-07-04 BR BRPI0813707-2A patent/BRPI0813707B1/pt active IP Right Grant
- 2008-07-04 UA UAA201001004A patent/UA99833C2/ru unknown
- 2008-07-04 KR KR1020107003000A patent/KR101544624B1/ko active Active
- 2008-07-04 SI SI200830754T patent/SI2164844T1/sl unknown
- 2008-07-04 PT PT08773881T patent/PT2164844E/pt unknown
- 2008-07-04 DK DK08773881.1T patent/DK2164844T3/da active
- 2008-07-04 WO PCT/EP2008/005508 patent/WO2009007074A1/de not_active Ceased
- 2008-07-04 EA EA201000094A patent/EA017281B1/ru unknown
- 2008-07-04 JP JP2010515398A patent/JP5426544B2/ja active Active
- 2008-07-04 PL PL08773881T patent/PL2164844T3/pl unknown
- 2008-07-04 CA CA2692867A patent/CA2692867C/en active Active
- 2008-07-11 AR ARP080102976A patent/AR067505A1/es active IP Right Grant
-
2009
- 2009-12-02 CO CO09137749A patent/CO6170360A2/es active IP Right Grant
- 2009-12-03 CO CO09138245A patent/CO6270257A2/es active IP Right Grant
- 2009-12-31 IL IL203091A patent/IL203091A/en active IP Right Grant
- 2009-12-31 IL IL203094A patent/IL203094A/en active IP Right Grant
-
2010
- 2010-02-09 EC EC2010009953A patent/ECSP109953A/es unknown
- 2010-02-10 EC EC2010009957A patent/ECSP109957A/es unknown
- 2010-02-11 ZA ZA2010/01023A patent/ZA201001023B/en unknown
-
2012
- 2012-08-03 US US13/565,914 patent/US8658643B2/en active Active
- 2012-09-13 CY CY20121100840T patent/CY1113137T1/el unknown
-
2013
- 2013-03-05 US US13/785,580 patent/US8927540B2/en active Active
- 2013-03-05 US US13/785,471 patent/US8921357B2/en active Active
-
2014
- 2014-01-07 US US14/149,110 patent/US9062029B2/en active Active
- 2014-09-25 US US14/496,746 patent/US9284300B2/en active Active
-
2015
- 2015-01-15 CY CY20151100033T patent/CY1115925T1/el unknown
- 2015-01-22 US US14/602,921 patent/US9403799B2/en active Active
-
2017
- 2017-01-20 HR HRP20170100TT patent/HRP20170100T1/hr unknown
- 2017-01-26 CY CY20171100120T patent/CY1118498T1/el unknown
-
2022
- 2022-05-13 NO NO2022015C patent/NO2022015I1/no unknown
- 2022-05-20 LT LTPA2022009C patent/LTC2164843I2/lt unknown
- 2022-05-25 LU LU00264C patent/LUC00264I2/fr unknown
- 2022-05-25 HU HUS2200024C patent/HUS2200024I1/hu unknown
- 2022-05-30 NL NL301176C patent/NL301176I2/nl unknown
- 2022-06-02 FR FR22C1024C patent/FR22C1024I2/fr active Active
- 2022-06-10 CY CY2022017C patent/CY2022017I2/el unknown